Important milestone - funding secured

Moroxite AB has successfully raised SEK 22 million— backed by current owners and a small number of selected new investors.

This funding will support the continued development of Moroxite’s products for spinal fusion and fracture fixation.

‘We are pleased to have secured this funding. It will enable us to reach the first FDA clearance for our fracture fixation product in 2026.’

-Semmy Rülf, Chairman of the Board 

More details in the recent article on Moroxite AB published by Rapidus